Novavax, Inc. (NASDAQ:NVAX) – Early Knowledge Exhibits Novavax’s COVID-19 Vaccine Triggers Immune Response To Omicron

Novavax Inc (NASDAQ: NVAX) stated its two-dose COVID-19 vaccine successfully generates an immune response in opposition to the Omicron variant, in keeping with early knowledge.

  • Although the corporate stated neutralization in opposition to the Omicron variant was “4-fold decrease” than it was in opposition to the unique pressure of the virus, suggesting {that a} booster shot or a brand new Omicron-specific vaccine can be helpful.
  • A 3rd shot six months after the primary two doses indicated a rise in antibodies to ranges related to safety seen in earlier massive medical trials.
  • Associated Hyperlink: Novavax Stories Initiation Of PREVENT-19 COVID-19 Vaccine Part 3 Trial Booster Examine.
  • “We’re inspired that boosted responses in opposition to all variants have been corresponding to these related to excessive vaccine efficacy in our Part 3 medical trials, suggesting that NVX-CoV2373 can play an necessary function within the ongoing battle in opposition to new variants,” stated Gregory Glenn, President of Analysis and Growth, Novavax.
  • Additional, knowledge from the pediatric growth of Novavax’s PREVENT-19 Part 3 trial confirmed sturdy immune responses in adolescents, in opposition to a big selection of variants, together with Omicron, following a 2-dose collection. 
  • Responses in adolescents have been 2- to 4-fold greater than adults in opposition to all evaluated variants.
  • Novavax is creating an omicron-specific vaccine and expects to start manufacturing doses of the variant-specific shot in January.
  • Value Motion: NVAX shares are up 5.81{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} at $193.95 through the premarket session on the final test Thursday.

Source link